Keros Therapeutics, Inc.

Healthcare · Biotechnology · United States

Last price 11.36 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 225.24M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics to treat patients with disorders linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. It develops rinvatercept, which acts as a ligand trap and inhibits the biological effects of myostatin and activin A in Phase 1 clinical trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis; and elritercept to target TGF-ß signaling pathways to address diseases that...